Antituberculosis therapy and current global guidelines

Giovanni Battista Migliori, Giovanni Sotgiu, Rosella Centis, Malgorzata Grzemska, Dennis Falzon, Haileyesus Getahun, Mario C. Raviglione

Research output: Chapter in Book/Report/Conference proceedingChapter


The WHO Stop-TB Strategy has dramatically improved the control of TB worldwide. The emergence and the spread of anti-TB drug resistance can be prevented by the prescription of an effective anti-TB therapy. Drug sensitivity testing results are helpful to identify the most effective anti-TB drugs. WHO recommends to treat new TB cases for 6 months (H, R, Z, and E for 2 months, and H and R for other 4 months). WHO recommends to prescribe ART in all TB/HIV coinfected individuals (within the first 2 months after the start of the anti-TB therapy). Clinical management of adverse events due to anti-TB drugs increases the probability of treatment success.

Original languageEnglish
Title of host publicationCurrent and Emerging Diagnostics, Therapeutics and Vaccines for Tuberculosis
PublisherFuture Medicine Ltd.
Number of pages21
ISBN (Print)9781780840222, 9781780841113
Publication statusPublished - Oct 1 2011

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Antituberculosis therapy and current global guidelines'. Together they form a unique fingerprint.

Cite this